Brazilian Dengue Vaccine Effective for Up to Five Years

ArchivedSingle Source|1 articles|1 sources|1 blocks

Detected: Updated: Analyzed:

Healthcare

NarrativeRadar Analysis·Reviewed by M. Reyes·AI-assisted, editorially supervised

Reported Facts

Observable data points shared across all narratives

•The vaccine was developed and tested in Brazil.
•Effectiveness against dengue fever lasts up to five years post-vaccination.
•The vaccine targets multiple dengue virus serotypes.
•It is part of Brazil's efforts to control dengue outbreaks.

What Could Happen If...

▸Brazilian health authorities expand vaccine distribution Dengue incidence could decline substantially, benefiting public health and reducing healthcare costs.

Key Actors

Countries

🌍Latin America

Source Coverage

REGIONAL

1 articles

More coverage on this story

More on Latin America

Signals

Single-block coverage

Primary Sources (1)

REGIONALAgencia BrasilVacina brasileira contra a dengue mantém eficácia por até 5 anos

A dengue vaccine developed in Brazil has been shown to maintain its effectiveness for up to five years after administration. This long-lasting protection could significantly reduce dengue fever cases in Brazil and other affected regions, improving public health outcomes. The vaccine's sustained efficacy supports its use in ongoing dengue prevention programs.